A neurotensin antagonist, SR 48692, inhibits colonic responses to immobilization stress in rats. 1996

I Castagliuolo, and S E Leeman, and E Bartolak-Suki, and S Nikulasson, and B Qiu, and R E Carraway, and C Pothoulakis
Division of Gastroenterology, Beth Israel Hospital, Harvard Medical School, Boston, MA 02215, USA.

We previously reported that short-term immobilization stress of rats causes increased colonic mucin release, goblet cell depletion, prostaglandin E2 secretion, and colonic mast cell activation, as well as increased colonic motility. The purpose of this study was to investigate whether neurotensin (NT), a peptide expressed in both brain and digestive tract, participates in these responses. Rats were pretreated with SR 48692 (1 mg/kg, i.p.), an NT antagonist, 15 min before immobilization (30 min). The administration of the antagonist significantly inhibited stress-mediated secretion of colonic mucin, prostaglandin E2, and a product of rat mast cells, rat mast cell protease II (P < 0.05), but did not alter the increase in fecal pellet output caused by immobilization stress. Immobilization stress also resulted in a quantifiable decrease in the abundance of NT receptor mRNA in rat colon compared with that in colonic tissues from nonimmobilized rats as measured by densitometric analysis of in situ hybridization studies (P < 0.03). We conclude that the peptide NT is involved in colonic goblet cell release and mucosal mast cell activation after immobilization stress.

UI MeSH Term Description Entries
D009077 Mucins High molecular weight mucoproteins that protect the surface of EPITHELIAL CELLS by providing a barrier to particulate matter and microorganisms. Membrane-anchored mucins may have additional roles concerned with protein interactions at the cell surface. Mucin
D011720 Pyrazoles Azoles of two nitrogens at the 1,2 positions, next to each other, in contrast with IMIDAZOLES in which they are at the 1,3 positions.
D011804 Quinolines
D012149 Restraint, Physical Use of a device for the purpose of controlling movement of all or part of the body. Splinting and casting are FRACTURE FIXATION. Immobilization, Physical,Physical Restraint,Physical Immobilization,Physical Restraints,Restraints, Physical
D003106 Colon The segment of LARGE INTESTINE between the CECUM and the RECTUM. It includes the ASCENDING COLON; the TRANSVERSE COLON; the DESCENDING COLON; and the SIGMOID COLON. Appendix Epiploica,Taenia Coli,Omental Appendices,Omental Appendix,Appendices, Omental,Appendix, Omental
D005772 Gastrointestinal Transit Passage of food (sometimes in the form of a test meal) through the gastrointestinal tract as measured in minutes or hours. The rate of passage through the intestine is an indicator of small bowel function. GI Transit,GI Transits,Gastrointestinal Transits,Transit, GI,Transit, Gastrointestinal,Transits, GI,Transits, Gastrointestinal
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D012333 RNA, Messenger RNA sequences that serve as templates for protein synthesis. Bacterial mRNAs are generally primary transcripts in that they do not require post-transcriptional processing. Eukaryotic mRNA is synthesized in the nucleus and must be exported to the cytoplasm for translation. Most eukaryotic mRNAs have a sequence of polyadenylic acid at the 3' end, referred to as the poly(A) tail. The function of this tail is not known for certain, but it may play a role in the export of mature mRNA from the nucleus as well as in helping stabilize some mRNA molecules by retarding their degradation in the cytoplasm. Messenger RNA,Messenger RNA, Polyadenylated,Poly(A) Tail,Poly(A)+ RNA,Poly(A)+ mRNA,RNA, Messenger, Polyadenylated,RNA, Polyadenylated,mRNA,mRNA, Non-Polyadenylated,mRNA, Polyadenylated,Non-Polyadenylated mRNA,Poly(A) RNA,Polyadenylated mRNA,Non Polyadenylated mRNA,Polyadenylated Messenger RNA,Polyadenylated RNA,RNA, Polyadenylated Messenger,mRNA, Non Polyadenylated
D012697 Serine Endopeptidases Any member of the group of ENDOPEPTIDASES containing at the active site a serine residue involved in catalysis. Serine Endopeptidase,Endopeptidase, Serine,Endopeptidases, Serine
D015232 Dinoprostone The most common and most biologically active of the mammalian prostaglandins. It exhibits most biological activities characteristic of prostaglandins and has been used extensively as an oxytocic agent. The compound also displays a protective effect on the intestinal mucosa. PGE2,PGE2alpha,Prostaglandin E2,Prostaglandin E2alpha,PGE2 alpha,Prepidil Gel,Prostaglandin E2 alpha,Prostenon,E2 alpha, Prostaglandin,E2, Prostaglandin,E2alpha, Prostaglandin,Gel, Prepidil,alpha, PGE2,alpha, Prostaglandin E2

Related Publications

I Castagliuolo, and S E Leeman, and E Bartolak-Suki, and S Nikulasson, and B Qiu, and R E Carraway, and C Pothoulakis
August 1996, Brain research,
I Castagliuolo, and S E Leeman, and E Bartolak-Suki, and S Nikulasson, and B Qiu, and R E Carraway, and C Pothoulakis
June 1994, British journal of pharmacology,
I Castagliuolo, and S E Leeman, and E Bartolak-Suki, and S Nikulasson, and B Qiu, and R E Carraway, and C Pothoulakis
February 2002, Neuroscience letters,
I Castagliuolo, and S E Leeman, and E Bartolak-Suki, and S Nikulasson, and B Qiu, and R E Carraway, and C Pothoulakis
February 1996, British journal of pharmacology,
I Castagliuolo, and S E Leeman, and E Bartolak-Suki, and S Nikulasson, and B Qiu, and R E Carraway, and C Pothoulakis
July 2013, Bioorganic & medicinal chemistry,
I Castagliuolo, and S E Leeman, and E Bartolak-Suki, and S Nikulasson, and B Qiu, and R E Carraway, and C Pothoulakis
October 1994, Psychopharmacology,
I Castagliuolo, and S E Leeman, and E Bartolak-Suki, and S Nikulasson, and B Qiu, and R E Carraway, and C Pothoulakis
January 1997, Neuropharmacology,
I Castagliuolo, and S E Leeman, and E Bartolak-Suki, and S Nikulasson, and B Qiu, and R E Carraway, and C Pothoulakis
October 2006, Behavioral neuroscience,
I Castagliuolo, and S E Leeman, and E Bartolak-Suki, and S Nikulasson, and B Qiu, and R E Carraway, and C Pothoulakis
January 1999, Anticancer research,
I Castagliuolo, and S E Leeman, and E Bartolak-Suki, and S Nikulasson, and B Qiu, and R E Carraway, and C Pothoulakis
January 1994, Life sciences,
Copied contents to your clipboard!